Market cap data unavailable. We couldn't positively verify this ticker's market cap is under $500M. Verify independently before trading.
Exousia Bio, Inc.
- Market Cap
- Unavailable
- Price
- $0.165
- % Change (Daily % change from the live per-ticker quote feed.)
- +2.17%
- Volume
- 1.0K
About
Exousia Bio, Inc. is a biotechnology company that designs, develops, and manufactures mammalian- and plant-derived exosomes using proprietary technologies for nucleic acid loading and targeted delivery to tissues and cells. The company's platform enables the custom production of exosomes with enhanced genetic functionality that can selectively target specific cells to address diseases. The company was formerly known as LAMY and changed its name to Exousia Bio, Inc. in January 2026.
Quick stats
Shares outstanding—
Computed float2.5M
Float / sharesUnknown
Key info
SectorConsumer Defensive
IndustryEducation & Training Services
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001939937
Websitehttps://exousiabio.com
AI Summary
AI-generated19d agostandardbullishdilution
Exousia Bio Nearing Completion of Milestone Multimillion-Dollar Capital Investment
Exousia Bio is finalizing a mid-seven-figure investment to fund its next operational growth phase, with closing expected prior to Labor Day.
The incoming capital will directly fund facility upgrades to a state-of-the-art Level 2 laboratory, expand international joint ventures, and accelerate commercial scale-up for partner NexTel Medical (MAJI).
CEO Matthew Dwyer stated the funding enables the company to advance oncology research into additional indications and equips MAJI to meet market demand.
Red flags
- transaction not yet closed ('nearing completion')
- vague investment amount ('mid-seven-figure')
- OTC/Pink Sheet listing status